A plant based retinol alternative: discovering the power of Atractylodes lancea 

The search for a clinically validated plant-based retinol alternative has been one of cosmetic science’s most persistent research priorities over the past seven decades. Atractylodes lancea rhizome extract (ALRE) now presents itself as a credible answer to that challenge: an ingredient with direct nuclear receptor activity, a documented transcriptomic overlap with retinol, and clinical data spanning two 56-day human trials.  

This article examines the mechanistic, clinical, and formulation evidence behind ALRE as a plant based retinol alternative, drawing on data presented by Provital at IFSCC 2026 in Perth, Australia. 

The retinol dilemma: proven efficacy, limited tolerability 

Retinol and its parent compound, all-trans retinoic acid, remain the reference standard for treating visible skin aging, yet their clinical use is consistently limited by irritation, dryness, and photoinstability. This tension, undeniable efficacy paired with a real tolerability ceiling, is the central problem driving research into botanical alternatives. 

How retinoids work? 

Retinoids exert their effects by binding to nuclear Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs). This receptor binding regulates gene transcription cascades that drive epidermal proliferation and stimulate fibroblasts to increase synthesis of structural proteins within the extracellular matrix, including collagen types I and III, while simultaneously inhibiting matrix metalloproteinase transcription (Fisher & Voorhees, 1996). 

Balancing efficacy and retinol skin irritation in modern formulations 

The clinical signature of this receptor activation is often accompanied by “retinization” a symptom complex including transient erythema, scaling, elevated transepidermal water loss, and neurosensory burning or stinging. Retinol irritation of this kind is a leading cause of product discontinuation, and retinol’s extreme photolability further restricts its use to evening-only application protocols, typically paired with mandatory sunscreen co-use (Mukherjee et al., 2006). 

Retinol alternative for sensitive skin: the unmet need 

Formulators serving sensitive-skin populations face a structural gap: no ingredient has offered retinol-equivalent receptor engagement without triggering the inflammatory cascade responsible for irritation. This gap is not marginal, in Provital’s poster (A true retinol-like active with no irritation: mechanistic, transcriptomic and clinical evidence, 2026), within Study 1 clinical cohort, 30% of participants carried a diagnosed sensitive-skin profile, underscoring how large this underserved segment actually is within the anti-aging category. 

IFSCC 2026: presenting ALRE’s transcriptomic profile and mechanism 

At the IFSCC 2026 Congress, Provital presented in vitro and in vivo evidence positioning ALRE as a mechanistically validated retinoid surrogate rather than a simple antioxidant. The data set spans receptor-binding assays, RNA sequencing, and two double-blind human trials, giving the ingredient a multi-layered evidentiary base. 

RARα activation: a 20 % increase in the luciferase assay 

In a HEK-RARα-Luc reporter assay, treatment with ALRE produced a statistically significant 20% increase in RARα activation relative to untreated controls, confirming direct nuclear receptor engagement rather than an indirect, downstream mechanism. This distinction matters: it places ALRE in the same mechanistic category as classical retinoids, rather than the antioxidant-driven category occupied by some other botanical actives. 

Atractylodes lancea: from traditional medicine to cosmetic science 

Atractylodes lancea has a documented history in East Asian ethnopharmacology, and its modern cosmetic application represents a translation of traditional therapeutic use into evidence-based skincare science. 

Atractylodes rhizome: origin, history and bioactive profile 

The rhizome, traditionally referred to as Cangzhu, comes from a perennial herb of the Asteraceae family and has long been used in East Asian medicine for its anti-inflammatory and metabolic properties. Its bioactive compounds are concentrated within secretory cavities in the rhizome tissue, a structural feature that underpins its chemical richness (Sun et al., 2026). 

Phytochemical characterization and bioactive extractions 

Advanced analytical techniques, including gas chromatography-mass spectrometry and liquid chromatography-triple time-of-flight mass spectrometry, have identified more than 300 individual chemical constituents within the rhizome matrix. The two dominant compound classes are lipophilic sesquiterpenoids, including beta-eudesmol, atractylon, and hinesol and conjugated polyacetylenes, represented primarily by atractylodin (Qu et al., 2024). 

Transcriptomic regulation of collagen type I and hyaluronic acid 

RNA sequencing analysis of Normal Human Dermal Fibroblasts (NHDF) treated with either 0.13% ALRE or 10 micromolar retinol revealed approximately 79% overlap in regulated genes between the two treatments, confirming highly similar functional profiles at the transcriptomic level. This degree of concordance validates ALRE as a genomic retinol equivalent, not merely a topical anti-aging active with surface-level effects. 

Complementary ELISA and Fastin™ dye-binding assays demonstrated that ALRE treatment produced dose-dependent increases in collagen type I, elastin, and hyaluronic acid within the same fibroblast cultures, the same structural proteins targeted by classical retinoid therapy. 

Overcoming retinol irritation: the role of TRPV1 non-activation 

ALRE’s central differentiation from retinol lies not in what it activates, but in what it does not: the TRPV1 receptor, a cation channel directly implicated in retinoid-induced burning and erythema. 

Cellular pathways: why ALRE avoids the pro-inflammatory cascade 

In Fluo-4 calcium influx assays using human TRPV1-expressing HEK293 cells, 50 micromolar retinol induced a strong intracellular calcium response, confirming channel activation, while 0.52% ALRE produced no measurable activation, remaining indistinguishable from vehicle controls. This finding is reinforced at the gene expression level: retinol treatment upregulated pro-inflammatory mediators including CCL2, CXCL6, CXCL8, PTGES, and PTGIS, whereas ALRE showed approximately five-fold lower CXCL8 induction and – reduced PTGES expression, the enzyme responsible for prostaglandin E2 synthesis linked to vascular redness and edema. 

Provital at IFSCC 2026: Atractylodes lancea from research to formulation 

A depigmenting effect without retinol’s irritant profile 

Using a Reconstructed Human Pigmented Epidermis model, retinol at 10 micromolar reduced epidermal melanin content by 24% relative to untreated controls, while ALRE achieved a dose-dependent reduction of up to 37%. Histological analysis using Fontana-Masson staining confirmed reduced melanosome density without disrupting epidermal architecture or melanocyte viability, positioning ALRE as a dual-function plant-based retinol alternative addressing both structural ECM anti-aging and tone-evening applications within a single formulation dose. 

Provital: formulating next-generation phyto-actives 

Presented under the IFSCC 2026 theme “Solving the Sustainable Beauty Equation,” Provital’s research reflects a broader industry direction toward evidence-generation standards for botanical actives that mirror the rigor traditionally applied to synthetic ingredients receptor assays, transcriptomic profiling, and randomized clinical trials, rather than efficacy claims based on traditional use alone. 

Clinical results over 56 days: firmness, wrinkles and radiance 

Study 1 – sensitive-skin cohort (n=51, 56 days): A split-face trial involving 51 participants across diverse skin types — 30% with clinically diagnosed sensitive skin — demonstrated statistically significant improvements with 2% ALRE over 56 days: wrinkle depth reduced by 10.8%, firmness improved by 6.8%, elasticity increased by 5.7%, radiance rose by 16.5%, and hydration increased by 9.6%. 

Study 2 – head-to-head vs. 0.3% retinol (n=62, 56 days): In 62 Asian women applying SPF 50 daily throughout the trial, ALRE achieved clinical parity in wrinkle depth, firmness, and elasticity relative to 0.3% retinol — the maximum EU Regulation 2024/996 permitted concentration — while delivering a superior radiance benefit. The zero-irritation tolerability record across both studies confirms that this efficacy is achieved without the barrier disruption or nociceptive signaling associated with classical retinol. 

FAQ | Plant-based retinol alternative: Atractylodes lancea 

Q: Is a plant-based retinol alternative as effective as retinol for anti-aging?  

A: In Provital’s head-to-head trial (n=62, 56 days), ALRE matched 0.3% retinol — the maximum EU-permitted concentration — on wrinkle depth, firmness, and elasticity, and delivered superior radiance. At the transcriptomic level, ALRE regulates 79% of the same genes as retinol in dermal fibroblasts, including HAS2, TGF-β axis genes, and pro-collagen pathways. The equivalence is mechanistic, not just clinical.  

Q: What is Atractylodes lancea and how does it work as a retinol alternative?  

A: Atractylodes lancea is a perennial herb of the Asteraceae family whose rhizome extract (ALRE) contains sesquiterpenoids and polyacetylenes that directly activate nuclear Retinoic Acid Receptors (RARα). This RAR agonism — confirmed by a 20% increase in a luciferase reporter assay — drives the same collagen synthesis, ECM remodeling, and hyaluronic acid upregulation as classical retinoids, without engaging the TRPV1 ion channel responsible for retinoid irritation. 

Q: At what concentration and in what product formats should ALRE be used to match retinol performance?  

A: Clinical data show that 2% ALRE in a split-face leave-on format delivers statistically significant anti-aging outcomes over 56 days across five endpoints — including wrinkle depth, firmness, elasticity, radiance, and hydration — in a diverse panel including 30% sensitive-skin subjects. In the head-to-head trial against 0.3% retinol (the EU-maximum), ALRE achieved clinical parity on structural parameters and superior radiance. Recommended use is in leave-on serums, night treatments, and body formulations; the ingredient’s water solubility, cold-processability, and broad pH stability make it compatible with emulsion, gel, and aqueous formats without the stability or photosensitivity constraints that restrict retinol to evening-only use. 

Key takeaways 

• Mechanism of action: ALRE directly activates RARα (+20% versus control), the same nuclear receptor pathway targeted by classical retinoids. 

• Transcriptomic validation: RNA sequencing confirms approximately 79% overlap in gene regulation between ALRE and retinol in NHDF, encompassing extracellular matrix synthesis pathways. 

• Irritation profile: ALRE produces zero TRPV1 activation and approximately five-fold lower CXCL8 induction than retinol, decoupling efficacy from the inflammatory cascade responsible for retinization. 

• Depigmentation: ALRE reduced epidermal melanin by up to 37% in a Reconstructed Human Pigmented Epidermis model, exceeding retinol’s 24% reduction. 

• Clinical validation: Two 56-day double-blind trials demonstrate anti-aging parity with 0.3% retinol, with superior radiance outcomes and favorable tolerability. 

For further information or insights on cosmetic innovation, please do not hesitate to contact our team of experts, who are available to provide guidance and support in selecting the most suitable solutions for your requirements.